Septic arthritis is a severe and rapidly debilitating disease associated with severe joint pain, inflammation and oxidative stress. Nitroxyl (HNO) has become a nitrogen oxide of significant interest due to its pharmacological endpoints that are potentially favorable for treating varied diseases. However, whether HNO also serves as a treatment to septic arthritis is currently unknown. The aim of this study was to investigate the effect of the HNO donor, Angeli's salt (AS), in the outcome of chronic Staphylococcus aureus (S. aureus)-induced septic arthritis in mice. Daily treatment with AS inhibited mechanical hyperalgesia and inflammation (edema, leukocyte migration, cytokines release and NF-κB activation, and oxidative stress) resulting in reduced disease severity (clinical course, histopathological changes, proteoglycan levels in the joints, and osteoclastogenesis). In addition, AS decreased the number of S. aureus colony forming unities in synovial tissue, enhanced the bactericidal effect of macrophages and inhibited the worsening of systemic inflammatory response (leukocyte counts in the lung and systemic proinflammatory cytokine concentration). Our results suggest for the first time the therapeutic potential of AS in a model of septic arthritis by mechanisms involving microbicidal effects, antiinflammatory actions and reduction of disease severity.
Introduction
Septic arthritis is a highly destructive joint disease with rapid progression affecting patients, which is still a major medical challenge because of its high prevalence and poor prognosis regarding to joint functions [1] . The fatality rate for septic arthritis is high (5-15%) and permanent loss of joint functions due to cartilage damage and bone erosion develops in 25-50% of patients [2] . Staphylococcus aureus (S. aureus) is the major cause of septic arthritis. Immunosuppressive treatments, joint implant and disease-induced articular lesions increase the incidence of septic arthritis as observed, for instance, in rheumatoid arthritis patients [3] . In this context, it is important to search for novel therapies for septic arthritis.
The synovial membrane inflammation in the septic arthritis leads to tissue destruction and dysfunction, resulting into significant morbidity [2] . Activated resident and recruited cells produce inflammatory mediators shaping the immune response and tissue destruction. Neutrophils are highly motile phagocytic cells acting as the first-line innate immune system defense against infection [4] . Neutrophils are in high counts in the joints of septic arthritis patients during the course of the disease [5] . Neutrophils contribute to the local production of inflammatory mediators and to inflict joint damage, perpetuating the inflammatory response by contributing to the recruitment of macrophages and monocytes that are followed by T cells [5, 6] . Both Th1 and Th17 cells contribute to reduce S. aureus infection [7] . The majority of these mechanisms are coordinated by a number of cytokines and chemokines with the contribution of free radicals such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) [8] . Thus, the influx of neutrophils and other immune cells into joints represent an important target for the development of new therapeutic strategies for septic arthritis.
The therapeutic strategy of septic arthritis uses two main approaches: treating the infection with broad-spectrum antibiotic parentally prior to the knowledge on the type of microorganism and resistance patterns, and treating the symptoms by using the cotreatment with corticosteroid to prevent the neutrophils functions and down-regulate the severity of septic arthritis [1] . Nevertheless, during the last decades no new major therapies have been developed to reduce the joint inflammation together with prevention of joint lesion and dysfunction in septic arthritis [3] . The importance of antibiotics and anti-inflammatory drugs in the treatment of septic arthritis suggests the importance of identifying novel molecules that share microbicidal and anti-inflammatory properties.
Nitric oxide (NO •   ) is an abundant reactive radical that acts as an important oxidative biological signaling molecule in a wide variety of diverse physiological processes, including neurotransmission, blood pressure regulation, smooth muscle relaxation, pain and analgesia, immune regulation and host defense mechanisms [9] [10] [11] . A critical role has been proposed for NO
• in septic arthritis regarding to the control of infection [12] , but its redox sibling, nitroxyl (HNO), has not been described. This is of particular importance since the HNO shares signaling activities with NO • . Notwithstanding, HNO can has an entirely separate signaling and unique biological activities when compared to NO
• , supporting the fact that HNO and NO • are different chemicobiological entities [13] . Such effects were demonstrated mainly in the cardiovascular system, including the ability of HNO to directly target thiols, the resistance of being scavenged by superoxide, to elevate plasma levels of calcitonin gene-related peptide (CGRP) and serve as a positive cardiac inotrope [14] [15] [16] . Furthermore, another important pharmacological action of HNO is the ability to elicit antioxidant effects [17] , preconditioning against ischemia/reperfusion injury [18] , induction of apoptosis, suppression of tumor angiogenesis [19, 20] , and inhibition of alcohol metabolism [21] . All the analyses of these properties of HNO require the use of donor compounds due to the metastability as a result of irreversible dimerization. This dimerization reaction makes the quantitative endogenous detection of HNO a challenge. Therefore, HNO donors are crucial tools to study its biological effects. Angeli's salt (AS) is the most well studied and characterized HNO donor [22] . Recently our group demonstrated for the first time the analgesic effect of HNO [23, 24] . In the first study, we demonstrated that the AS inhibited the mechanical hyperalgesia induced by carrageenan in rats via activation of sGC/cGMP/PGK/ATP-sensitive potassium channel signaling pathway and inhibition of cytokine production (e.g. TNF-α and IL-1β). Specifically, treatment with AS was capable of delivering HNO to dorsal root ganglia neurons [23] . Furthermore, AS also inhibited overt pain-like behavior by similar mechanisms activated in hyperalgesia models [24] . All these effects were mediated via HNO rather than nitrite (the other metabolite of Angeli's salt in acid conditions) or extracellular oxidation of HNO to NO• since the HNOselective scavenger, L-cystein, prevented the analgesic actions of AS [23, 24] . AS also inhibited chronic constriction injury-induced neuropathic pain by reducing spinal cord glial cell activation [25] . Despite these evidence suggested above, the effect of the HNO donor, AS, in other inflammatory conditions remains to be evaluated. The aim of the current study was to investigate the potential microbicide, antiinflammatory and antioxidants effects of the treatment with AS in an experimental model of septic arthritis in mice.
Material and methods

Animals
Male Swiss mice (25 g), from the Londrina State University, Londrina, Parana, Brazil, were used in this study. Mice were housed in standard clear plastic cages with free access to water and food, and temperature of 23°C ± 2. A 12/12 h light/dark cycle was used with lights on at 6 a.m. and off at 6 p.m. The behavioral tests were performed between 9 a.m. and 5 p.m. in a temperature-controlled room (23°C ± 2). Animal care and handling procedures were in accordance with the International Association for Study of Pain (IASP) guidelines, and approved by the Ethics Committee of the Londrina State University (OF.CIRC.CEUA 84/10, process number 33358.2010.36).
Materials and chemicals
The following materials were obtained from the sources indicated: NaCl 0.9% (Fresenius Kabi Brasil Ltda. Aquiraz, CE, Brazil), enzymelinked immunosorbent assay (ELISA) Ready-SET-Go! (eBioscience, San Diego, CA, USA) and PathScan (Cell Signaling, Beverly, MA, USA) kits. SV Total RNA Isolation system (Promega), Platinum SyBR Green qPCR SuperMIX UDG (Invitrogen,USA). 2,2-azino-bis (3-ethylbenzothiazoline-6-sulfonate) (ABTS), Nitroblue Tetrazolium (NBT), Trizol, Sodium Hydroxide (NaOH), 1,9-Dimethyl-Methylene Blue zinc chloride double salt (DMMB), Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich, St. Louis, MO, USA).
Synthesis of nitroxyl donor, Angeli's salt (AS)
AS (Na 2 N 2 O 3 , sodium trioxodinitrate) was synthesized by the condensation of hydroxylamine with an organic nitrate as previously described [26] . In brief, a solution of hydroxylamine hydrochloride was slowly treated with excess of sodium methoxide to yield the hydroxylamine and to prevent the saturation of the solution. After that, the formed mixture was diluted with cold methanol and filtered. The retained filtrated was diluted in another 2 equivalents of sodium methoxide in an ice slurry under stirring and mixed with the alkyl nitrate (RONO 2 ). The reaction was submitted to Argon to remove the oxygen for 3 h and the final solution was diluted with a half volume of cold diethyl ether and filtrated to retain the solid product. The solid product was washed successively with 3% of methoxide in methanol, just methanol and ether and dried for 10 min to obtain the final compound. To determine the stability of the compound, the UV absorption spectroscopy was used to determine the concentrations with coefficients at 250 nm (ε of 8000 M −1 cm) [26, 27] .
Mouse model of S. aureus-induced arthritis
S. aureus was obtained from ATCC (American Type Culture Collection, U.S.A.) number 6538. Twenty-four hours before each experiment, samples of bacteria were cultured in blood agar medium at 37°C. After 24 h, the plate was washed with sterile phosphate buffered saline (PBS) to obtain a bacterial suspension. The bacterial suspension was centrifuged and the pellet was re-suspended in sterile PBS to fit the McFarland 0,5 scale by visual comparison [28] . Septic arthritis was induced by local injection of 1×10 [5] [6] [7] CFU of S. aureus in 10 μl in sterile PBS into the right knee joints. Intra-articular (i.a.) injection of 10 μl of sterile saline was used as negative control group. To evaluate the intensity of arthritis, a clinical scoring was carried out using macroscopic inspection of the knee joints yielding a score of 0-4 for each limb (0 -normal, 1 -periarticular erythema, 2 -articular erythema and edema, 3 -function loss with difficult locomotion and articular extension, 4 -purulent process with abscess formation).
Electronic pressure meter test
The electronic pressure meter test was used to evaluate the articular hyperalgesia as previously described [29, 30] . It consists of a hand-held force transducer fitted with a polypropylene tip (IITC 152 Inc., Life Science Instruments, Woodland Hills, CA, USA). For this model, a large tip (4.15 mm 2 ) was adapted to the probe. An increasing perpendicular force was applied to the central area of the plantar surface of the hind paw to induce flexion of the femur-tibial joint followed by paw withdrawal. A tilted mirror below the grid provided a clear view of the hind paw. The electronic pressure-meter apparatus automatically recorded the intensity of the force applied when the paw was withdrawn. The test was repeated until three subsequently consistent measurements (i.e. the variation among these measurements was less than 1 g) were obtained. The flexion-elicited mechanical threshold was expressed in grams (g).
Leukocyte migration to the knee joint and bacterial recovery
Mice received S. aureus or vehicle into articular cavity and were euthanized at selected points after stimulus injection. The knee joint cavities were washed 3 times with 3.3 μl of sterile saline with 1 mM EDTA [30] . The total number of leukocytes was determined in a Neubauer chamber diluted in Turk's solution and differential cell counts were performed in Roselfeld stained slices using a light microscope. The results were expressed as the number of total of leukocytes, neutrophils or mononuclear cells per cavity. Additionally, the same samples were plated in blood agar to determine the bacterial load in the knee joints and the results were expressed as colony-forming unity (CFU) per cavity.
Proteoglycan quantification assay
Proteoglycan contents were determined using the method described by Burkhardt et al. with modifications [31] . Patella were carefully collected from each animal and fixed with formaldehyde (4%) overnight using a shaker. They were then transferred into a solution of formic acid (5%) and incubated for 4 h using a shaker for decalcification. Each patella was then placed into 50 μl papain digestion buffer consisting of a papain suspension (5 mg/ml) in calcium and magnesium-free PBS with 5 mM cysteine and 10 mM EDTA, pH 7.4. The samples were sealed and incubated in a water bath at 60°C overnight. After reaching room temperature, the samples were centrifuged for 10 min at 1000g to collect the condensation droplets. Next, 40 μl of the supernatants and of serial chondroitin sulfate solutions (standard curve; 50-1000 μg/ml) were placed into 96-well microtiter plates. The chondroitin sulfate standard solutions were also incubated with papain digestion buffer. Then, 300 μl of a 1,9-dimethylmethylene blue (DMMB; 50 mg/l) solution was added to each well, and the absorbance at 525 nm was measured immediately in a plate reader. The GAG content was calculated from the standard curve. The DMMB solution was prepared by dissolving 50 mg DMMB in 5 ml ethanol and diluting to a volume of 1000 ml with 0.2% (w/v) sodium formate buffer, pH 3.5.
Histopathological examination of knee joint slices
Mice were anesthetized and killed, then, knee joints from infected and non-infected mice were dissected out, decalcified, embedded in paraffin, and sectioned with a microtome. Tissue sections were stained with hematoxylin and eosin. All the slides were coded and assessed in a blinded manner by two observers with regard to the degree of synovitis (leukocyte infiltration score) and cartilage destruction.
Cytokine measurements
Mice were anesthetized and killed, and the knee joints from infected and non-infected mice were dissected out and frozen with liquid nitrogen. Then, samples were homogenized in saline, centrifuged (3600 rpm×4°C×15 min) and the supernatants were used to determine the levels of TNF-α, IL-1β, IL-33, IL-17 and IFN-γ. The results were expressed as pg per 100 mg of tissue. Blood samples were collected from a peripheral vein and kept on ice. Plasma was obtained by centrifugation at 400g for 20 min at 4°C, aliquots were stored at −80°C until the analysis. All measurements were performed using ELISA kits as per manufacturer's instructions.
NF-κB activation
The assessment of total and phosphorylated NF-κB was performed using ELISA kits. Mice were anesthetized and killed at selected time points after i.a. injection of S. aureus, and the knee joints were dissected out, frozen with liquid nitrogen and homogenized in lysis buffer. Lysates were centrifuged (3000 rpm×10 min×4°C), and the supernatants were used to assess the levels of total and phosphorylated NF-κB following the manufacturer's instructions. The results were obtained by comparing the optical density of samples and the samples' weight. Data were expressed as the total NF-κB/phospho NF-κB absorbances ratio per 100 mg of tissue.
Quantitative polymerase chain reaction (qPCR)
qPCR was performed as previously described [30] . Samples were homogenized in Trizol reagent and mRNA was extracted by using SV Total RNA Isolation system. All reactions were performed in triplicate using cycling conditions: 50°C for 2 min, 95°C for 2 min, followed by 50 cycles of 95°C for 15 s and 60°C for 30 s qPCR was performed in a LightCycler® Nano Instrument (Roche, Mississauga, ON, USA) and the sequence detection system by using the SYBR-green fluorescence. The primers used were: RANKL, sense: 5′-CCT GAG GCC CAG CCA TTT-3′, antisense: 5′-CTT GGC CCA GCC TCG AT-3′; RANK, sense: 5′-CTA ATC CAG GGA AGC AAA T-3′, antisense: 5′-GAC ACG GGC ATA GAG TCA GTT C-3′, OPG system, sense: 5′-GGA ACC CCA GAG CGA AAC ACA-3′, antisense: ANTISENSE 5′-CCT GAA GAA GGC CTC TTC ACA-3′; gp91 phox , sense: 5′-AGCYAYGAGGYGGTGATGTTAGTGG-3, antisense: 5′-CACAATATTTGTACCAGACAGACTTGAG-3; Cox-2, sense: 5′-GTGG-AAAAACCTCGTACCAGA-3′, antisense: 5′-GCTCGGCTTCCAGTATTGA-G-3′; Gr, sense: 5′-TFCGTGAATGTTGGATGTGTACCC-3′, antisense: 5′-CCGGCATTCTCCAGTTCCTCG-3; HO-1, sense: 5′-CCCAAAACTGGCCT-GTAAAA-3′, antisense: 5-CGTGGTCAGTCAACATGGAT-3; Gapdh, sense: 5′-CATACCAGGAAATGAGCTTG-3′, antisense: 5′-ATGACATCA-AGAAGGTGGTG-3. The expression of GAPDH mRNA was used as a control for tissue integrity in all samples.
NBT reduction
The superoxide anion production was determined by the reduction of the redox dye nitroblue tetrazolium (NBT) [32] . Frozen knee joint samples collected at indicated time points were homogenized with 500 μl of saline and 50 μl of the homogenate were placed in a 96-well plate, followed by the addition of 100 μl of NBT solution (1 mg/ml) and incubation for 1 h at 37°C. The supernatant was carefully removed, and the formazan precipitated was then solubilized by adding 120 μl of 2 M KOH and 140 μl of DMSO. The optical density was measured by microplate spectrophotometer reader (Multiskan GO Microplate Spectrophotometer, ThermoScientific, Vantaa, Finland) at 600 nm. The weight of samples was used for data normalization, and results were presented as NBT reduction (OD/mg of tissue).
Lipid peroxidation
Lipid peroxidation in the knee joints was assessed by determining the thiobarbituric acid reactive substances (TBARS) levels using a method previously described by Guedes et al., 2006 with modifications [32, 33] . In brief, trichloroacetic acid (10%) was added to the homogenate to precipitate proteins. This mixture was then centrifuged (1000g, 3 min at 4°C). The protein-free sample was extracted and thiobarbituric acid (0.67%) was added. The mixture was kept in water bath at 100°C for 15 min. Malondialdehyde (MDA), an intermediate product of lipoperoxidation, was determined by the difference between absorbances at 535 and 572 nm on a microplate spectrophotometer reader (Multiskan GO, Thermo Scientific) and the results were expressed as TBARS (nmol of MDA per mg of tissue).
GSH (reduced glutathione) levels
The samples from knee joint were collected at selected points post i.a. S. aureus injection and frozen at −80°C at least for 48 h until GSH assay. To determine the GSH levels were used a spectrophotometric method previously described by Ellman, 1959 with modifications [34] . In brief, the samples were homogenized with a polytron in ice-cold 0,02 M EDTA buffer solution. The homogenates were treated with 50% trichloroacetic acid. After 15 min, the homogenates were centrifuged at 1500g for 15 min and then 100 μl of supernatant was mixed with 200 μl of 0.4 M Tris-HCl, pH 8,0 and 10 μl of 10 mM dithiobisnitrobenzoic acid (DTNB) in methanol solution. After 5 min, the measurements were performed in 412 nm (Shimadzu UV-Vis Spectrophotometer UV-1650, Shimadzu Corporation, Kyoto, Japan). The results were expressed as nmol of GSH per mg of tissue using a standard GSH curve (0.09-100 nmol).
ABTS and FRAP assays
The ability of samples to resist oxidative damage was determined by its free radical scavenging (ABTS assay) and ferric reducing (FRAP assay) properties. The tests were adapted to a 96-well microplate format from previously described assays [35] . In brief, samples from knee joint were collected at selected points post i.a. S. aureus injection and homogenized immediately with ice-cold 1,15% KCl in volume of 500 μl. The homogenates were centrifuged (200g, 10 min at 4°C), and the supernatants were used in both assays. Diluted ABTS solution (200 μl) was mixed with 10 μl of sample in each well. After 6 min of incubation (25°C), the absorbance was measured at 730 nm (Multiskan GO Microplate Spectrophotometer, ThermoScientific, Vantaa, Finland). For FRAP assay, the supernatants (10 μl) were mixed with the freshly prepared FRAP reagent (150 μl). The reaction mixture was incubated at 37°C for 30 min, and the absorbance was measured at 595 nm (Multiskan GO ThermoScientific). The results of ABTS and FRAP assays were equated against a standard Trolox curve (0.02-20 nmol) and expressed as μM of Trolox equivalent per mg of tissue.
Minimum bactericidal concentration (MBC) determination
The microbicidal effect of AS on viable S. aureus was determined by minimum bactericidal concentration (MBC) with adaptations. In brief, 50 μl of bacterial suspension in suitable growth medium (Mueller Hinton broth) was added to the wells of a sterile 96-well plate already containing 50 μl of two-fold serially diluted AS (initial concentration: 10 μM) or NaOH (10 mM) in proper growth medium (Muller Hinton broth). The final volume in each well was 100 μl. Control wells were prepared with culture medium only, bacterial suspension only, AS only, and NaOH 10 mM only in amounts corresponding to the highest concentration used. Ciprofloxacin (50 μg), a broad-spectrum antibiotic, was utilized as positive control. The plate was incubated for 24 h and the supernatants was plated on blood agar for CFU counts. The results were expressed as the number of CFU per plate and compared with the positive and negative controls.
Cell culture
Mouse bone marrow-derived macrophages (BMDMs) were generated from femurs of 6-to 8-week-old mice and differentiated during 6 days in RPMI media plus 20% supernatant from L929 cells expressing mouse macrophage colony-stimulating factor (MCSF). For the killing assay, MØs (1×10 6 /well) were plated in 24-well plates to adhere overnight. After that, cells were pretreated with AS (10 μM) or vehicle for 1 h followed by infection with S. aureus [multiplicity of infection (MOI)=3]. Other wells were pre-treated with L-cystein (3 mM, 30 min) before AS (10 μM). The plates were centrifuged for 3 min at 5000 rpm and returned to the cell incubator for 3 h. The cells were lysed by addition of Triton X-100 0,2%. The lysates were serially diluted 1:10 in 1×PBS and plated on blood agar plates incubated overnight at 37°C.
Lung analysis
Lungs were washed twice using 1 ml saline with 1 mM EDTA per animal. Each flush consisted of three slow up and down movements. The total number of leukocytes was determined in a Neubauer chamber diluted in Turk's solution and the differential cell counts were determined in Roselfeld stained slices using a light microscope. The results were expressed as the number of total of leukocytes, neutrophils or mononuclear cells in the BALF. Additionally, the same lungs were processed to measure the neutrophil accumulation by myeloperoxidase (MPO) assay. The absorbance of the tissue supernatant was compared with a standard curve of mouse peritoneal neutrophils, and the results were expressed as the number of neutrophils per mg of tissue.
Hepatic and renal toxicity
To investigate the potential of Angeli's Salt to cause hepatic or renal toxicity, serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine and urea were determined. For this test, the blood samples from mice treated over 28 days was collected and then centrifuged (0.4g×4°C×20 min) to obtain the serum. After that, the levels of ALT, AST, creatinine and urea were determined using a diagnostic kit from Labtest according to the manufacturer's instructions.
Experimental protocols
In dose-response experiments of stimulus (S. aureus), mice (n=6 per group per experiment, representative of two independent experiments) were infected with 10 5 , 10 6 and 10 7 CFU/10 μl and the mechanical hyperalgesia and articular edema were evaluated over 27 days. Leukocyte recruitment to the knee joints was evaluated at the 28th day post-infection. , COX-2, HO-1, Gr, and RANKL/RANK/OPG system), oxidative stress (NBT reduction, TBARS assay, FRAP assay, ABTS assay and GSH assay), bacterial recovery and evaluation of systemic inflammatory parameters (leukocyte recruitment in the lungs and cytokine levels in the plasma) were evaluated 7, 14, 21 and 28 after i.a. injection of S. aureus (1×10 7 /10 μl). Serum samples were collected at the 28th day post-infection and AS treatment to evaluate possible renal and hepatic toxicity of the chronic treatment with AS by measuring the levels of ALT, AST, creatinine and urea. Fig. 1 shows the schematic protocol for in vivo experiments. The MBC (minimum bactericidal concentration) in vitro was tested to determine the lowest concentration of AS required to kill S. aureus. The "killing" assay was determined to verify the effect of HNO on bactericidal capacity of naïve macrophages. The vehicle (10 mM NaOH plus saline) treatment did not alter the responses.
Statistical analysis
The statistical analyses were performed using GraphPad Prism 6.0 (La Jolla, 5 CA). Results are presented as means ± SEM of two independent experiments. The n in the legends refers to the number of mice per group in each experiment. The differences between the experimental groups were compared by t-test or one-way ANOVA and individual comparisons were subsequently made by Tukey's post hoc test. The level of significance was set at P < 0.05 and are represented by symbols (* or #). Legends indicate the significance, otherwise a nonsignificant statistical difference was observed. accompanied by mechanical hyperalgesia (pain), joint edema, and leukocyte recruitment in a dose-dependent manner which peaked with 10 7 CFU/10 μl ( Fig. 2A-C ). Significant mechanical hyperalgesia and edema were observed starting at the 1st day after injection. The mechanical hyperalgesia peaked at day 13 and maintained its levels until day 28. At the 28th day, significant leukocyte recruitment in the knee joint was also observed. Overall, the doses of S. aureus presented similar effects except that joint edema was significant higher with the dose of 1×10 7 than the other doses, and 1×10 7 also present significant higher mechanical hyperalgesia and leukocyte recruitment compared to 1×10 5 at some time points. Therefore, the dose of S. aureus of 10 7 CFU/ 10 μl per joint was chosen for all subsequent experiments. In the next set of experiments, mice were daily treated with AS (0.3, 1 or 3 mg/kg, sc, 150 μl) or vehicle after i.a. injection of S. aureus (10 7 /10 μl/joint) and the intensity of mechanical hyperalgesia (Fig. 2D) , articular edema (Fig. 2E ) and clinical severity (Fig. 2F) were determined at indicated points over 27 days. AS significantly inhibited the mechanical hyperalgesia and articular edema induced by S. aureus starting at the third day and up to the 27th day of treatment in a dose-dependent manner, and the maximal effect was observed with AS at 3 mg/kg dose. Regarding the clinical severity score, the AS dose of 3 mg/kg reduced the septic arthritis clinical severity between 5 and 27 days (Fig. 2F) . No effect was observed with the doses of 0.3 and 1 mg/kg of AS in septic arthritis clinical severity. The treatment with AS was also effective in reducing the total of leukocytes, neutrophil and mononuclear cells recruitment to the knee joints at days 7, 14, 21 and 28 post S. aureus infection (Fig. 2G-I, respectively) . No significant effects were observed with the AS doses of 0.3 and 1 mg/kg (data not shown). The dose of 3 mg/kg of AS was selected for the next experiments considering the results of Fig. 2D -I. The treatment with vehicle had no effect on the evaluated parameters.
AS prevents S.aureus-induced joint damage
S. aureus induced a severe and progressive synovitis with leukocyte infiltration and cartilage destruction (Fig. 3A-C) . The treatment with AS inhibited septic arthritis-induced joint damage compared to vehicle as shown in the representative histological images (Fig. 3A) , which were scored for synovitis (Fig. 3B ) and cartilage destruction (Fig. 3C) . At day 7 post-infection, inflammatory cells had infiltrated the joint cavity, the synovial membrane was ticker than normal and the cartilage surface had been degraded. At day 14 post-infection, the synovial membrane had become ticker than that on day 7, and mice present enlargement of joint filled with dense and exudative inflammatory infiltrate with predominance of polymorphonuclear leukocytes over mononuclear cells. Cartilage destruction was much more severe than on day 7. At days 21 and 28 post-infection, the whole knee joint was almost completely degraded, disorganized, and only small parts of cartilage remaining. The septic arthritis development pattern was completely different in mice daily treated with AS (3 mg/kg, sc, 150 μl). AS treatment did not alter septic arthritis-induced synovitis and cartilage destruction scores at day 7 post-infection (Fig. 3A-C) . On the other hand, the number of inflammatory cells declined and cartilage damage was reduced by the 14th, 21st and 28th days. Further confirming cartilage destruction, septic arthritis induced a gradual loss of proteoglycan contents in the knee joints at days 7-28, which were inhibited by AS treatment (Fig. 3D) . Therefore, the septic arthritis disease tissue alterations were inhibited by AS.
AS inhibits S. aureus-induced mRNA expression of RANKL (RANKligand)/RANK (receptor activator of nuclear factor kappa)/OPG (osteoprotegerin) system
AS did not alter septic arthritis-induced RANKL (Fig. 4A) and RANK (Fig. 4B ) mRNA expression at day 7. On the other hand, AS inhibited S. aureus-induced RANKL and RANK mRNA expression at days 14, 21 and 
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28. AS inhibited S. aureus-induced-OPG mRNA expression (Fig. 4C ) in all intervals evaluated. Thus, the treatment with AS inhibited the mRNA expression of RANK and RANKL, which are responsible for inducing osteoclastogenesis and bone degradation in septic arthritis. OPG inhibits the binding of RANKL to RANK, but the inhibition of OPG mRNA expression by AS may not represent an enhancement of osteoclastogenesis and bone degradation since RANKL and RANK mRNA expression were also reduced.
AS inhibits S. aureus-induced cytokine production and NF-κB activation
The systemic treatment with AS inhibited S. aureus-induced IL-33
( Fig. 5A ), TNF-α (Fig. 5B) , IL-1β (Fig. 5C ), IL-17 ( Fig. 5D ) and IFN-γ (Fig. 5E ) production at all evaluated time points. Corroborating with the inhibition of cytokine production by AS, it also significantly inhibited S. aureus-induced NF-κB p65 activation (phosphorylated p65/total p65 ratio, Fig. 5F ) at all time points.
3.5. AS inhibits S. aureus induced-mRNA expression of gp91 phox and COX-2, and induces heme oxygenase-1 (HO-1) and glutathione reductase (Gr) mRNA expression AS inhibited S. aureus-induced of gp91 phox (Fig. 6A ) and COX-2 ( Fig. 6B ) mRNA expression at all evaluated intervals. The injection of S. aureus had no effect on Gr (Fig. 6C ) and HO-1 (Fig. 6D) mRNA expression. However, AS induced the expression of Gr (Fig. 6C ) and HO-1 (Fig. 6D ) since the day 7 and 14, respectively, and the effect remained significant at days 21 and 28. Therefore, AS inhibited septic arthritis-induced pro-oxidant enzymes and increased antioxidant enzymes mRNA expression in the knee joint, suggesting an important role of HNO in redox biology involved in septic arthritis.
AS inhibits S. aureus-induced oxidative stress
S. aureus infection increased the superoxide anion ( Fig. 7A ) and MDA production (Fig. 7B) . These results are in line with the reduced levels of endogenous antioxidants as observed in GSH (Fig. 7C) , FRAP (Fig. 7D) and ABTS free radical scavenging ability (Fig. 7E ) that were induced by S. aureus infection. AS inhibited S. aureus-induced super- aureus injection), knee joints were collected and processed to determine the mRNA expression of (A) RANKL, (B) RANK or (C) OPG system by qPCR. N=5 per group per experiment, representative of two independent experiments. *P < 0.05 compared with the saline group, #P < 0.05 compared with the S. aureus+vehicle group. One-way ANOVA followed by Tukey's test.
oxide anion and MDA production at all time points and inhibited the oxidative stress by restoring samples endogenous antioxidant capacity (Fig. 7) .
Microbicidal effect of AS in S. aureus infection
The treatment with AS diminished the CFU counts of S. aureus infected knee joints at all time points (Fig. 8A) . Corroborating with AS decreasing the in vivo bacterial load, AS also inhibited the S. aureus growth in vitro determined by MBC, a system without mammalian cells (Fig. 8B) . The treatment of the suspension of S. aureus with vehicle in an equivalent concentration used in vivo did not alter the number of viable bacteria on agar plates. Ciprofloxacin, an antibiotic that belongs to second-generation fluoroquinolone, was used as positive control and inhibited S. aureus growth. These results suggest the direct bactericidal effect of AS.
We further evaluated the involvement of HNO on ability of bone marrow-derived macrophages (BMDM) to kill S. aureus. BMDM presented small, although significant, effect on S. aureus growth per se, and treatment with AS (10 μM, 1 h) increased the bactericidal effect of naïve BMDM, decreasing the number of viable bacteria on agar plates (Fig. 8C) . In addition, the pretreatment with L-cystein (3 mM, 30 min), a HNO scavenger, abolished the effect of AS on macrophage killing of S. aureus (Fig. 8C) . L-cystein treatment at this concentration presented no effect. Thus, these results of Fig. 8C further confirm that the effects of AS are dependent on HNO.
AS inhibits S. aureus-induced systemic inflammatory response
The ability of AS to control local knee joint infection, and therefore, preventing systemic infection, was investigated by evaluating inflammatory parameters of lungs dysfunction and levels of pro-inflammatory cytokines. The treatment with AS inhibited S. aureus-induced total of leukocytes (Fig. 9A), neutrophils (Fig. 9B ) and mononuclear cells (Fig. 9C ) recruitment in the bronchoalveolar lavage fluid (BALF) at days 7, 14, 21 and 28 post-infection. AS also prevented neutrophil entrapment in the lungs as observed by a reduction of S. aureus-induced increase of myeloperoxidase (MPO) activity (Fig. 9D) in the lungs and decreased systemic blood concentration of TNF-α (Fig. 9E) and IL-1β (Fig. 9F ) at all time points in septic arthritis mice. These results demonstrate that AS prevented the worsening of local infection forearming the development of S. aureus-induced systemic infection.
Discussion
Pain, swelling and loss of joint function are major local symptoms in patients affected by septic arthritis [36] . The reduction of these inflammatory symptoms is a main therapeutic goal for septic arthritis treatment as well as rapid control of infection. The pharmacological treatment with a HNO donor, Angeli's salt (AS), markedly decreased the mechanical hyperalgesia and the entire inflammatory repertoire produced by the i.a. stimulus with S. aureus, the most prevalent cause of septic arthritis. Importantly, HNO decreased the CFU number of S. aureus in articular space and presented microbicide effects, showing that AS limits the bacterial load, therefore, diminishing the induction TNF-α, (C) IL-1β, (D) IL-17, (E) IFN-γ, and (F) total/phosphorylated NF-κB p65 ratio by ELISA at indicated points (7, 14, 21 and 28 days) post S. aureus injection. N=6 per group per experiment, representative of two independent experiments. *P < 0.05 compared with the saline group, #P < 0.05 compared with the S. aureus+vehicle group. One-way ANOVA followed by Tukey's test.
and chronicity of septic arthritis, tissue lesion and loss of joint function. In this sense, our findings add significant novelty to the pharmacological effects of HNO. Septic arthritis occurs post-sepsis as a result of hematogenous seeding, systemic bacteremia, direct introduction (e.g. perforation, therapeutic interventions, surgery) or extension from a contiguous focus of infection (such as skin or bone infections) [3] . Furthermore, there is increasing number of septic arthritis cases following prosthetic surgeries indicating that not only blood stream dissemination, but also local delivery of bacteria is an important inducer of septic arthritis. Another important point is that septic arthritis is also induced by common non multi-resistant bacteria [37] . Therefore, the S. aureusinduced arthritis mouse model by the i.a. injection exhibits several features involved in the inflammatory process within the joint cavity akin to those observed in humans, including the hyperalgesia, inflammation and loss of function.
In the present study, the S. aureus injection into femur-tibial joint produced a chronic mechanical hyperalgesia similarly to previous studies of bacterial infection [38] . S. aureus can directly activate sensory nociceptive neurons by producing pore forming molecules and formylated peptides [39] , which are bacterial virulence factors [40] . Other bacterial product such as LPS from gram-negative bacteria also induces mechanical hyperalgesia. LPS activates TLR4/MyD88 signaling in tissue resident immune cells, which produce cytokines that in turn sensitize nociceptor neurons to mechanical stimulus [41] . LPS also activates TRPA1 inducing nociceptor excitation and neurogenic inflammation [42] . AS treatment inhibited acute and chronic S. aureusinduced septic arthritis pain, an effect that can be independent of modulating the infection since AS inhibits LPS-induced hyperalgesia by delivering HNO to DRG neurons resulting in analgesia [23] . Therefore, although the analgesic effect was previously demonstrated, this is the first study to observe AS analgesia in septic inflammation.
A striking group of results was related to AS modulation of septic arthritis-induced inflammation versus tissue lesion. AS inhibits carrageenan-induced cytokine production [23] , suggesting that HNO can reduce inflammation. In this line, it was observed that AS treatment reduced total leukocyte, neutrophil and mononuclear cell recruitment to the knee joint together with a reduction of knee joint edema suggesting that there was a reduction of inflammation. AS inhibited the production of pro-inflammatory cytokines involved in the immune response against S. aureus including TNF-α, IL-1β, IL-33, IL-17 and IFN-γ as well as clinical signs characteristic of infection by S. aureus such as abscess formation [43] .
HNO can directly suppress vascular NOX2 activity [44, 45] . As such, AS also inhibited the tissue oxidative stress as observed by a reduction of lipid peroxidation, superoxide anion production and gp91 phox mRNA expression. The gp91 phox is also known as NOX2, and is highly expressed in non-phagocytic and phagocytic cells with the role of generating ROS that are essential for killing pathogens by the respiratory burst [46] and to amplify the inflammatory response [47] . In addition to NOX-2, COX-2 contributes to superoxide anion production as a by product of prostaglandin synthesis [47] , and AS inhibited septic arthritis-induced COX-2 mRNA expression. Besides inhibiting the production and systems involved in the production of ROS, AS also elicited antioxidant effects by an increase of FRAP and ABTS activity, glutathione system improvement and HO-1 mRNA expression. Indeed, HNO has the potential to serve as a one-electron reducer via donation of its hydrogen atom and also induces an increase in the expression and activity of the antioxidant protein HO-1, which has an important role in the cellular response to oxidative damage and suggest possible antioxidant mechanisms [48] . Some microorganisms use heme as a source of iron and therefore can be directly affected by the reduced heme availability in the presence of increased HO-1 expression [49] . S. aureus, for instance, takes up hemoglobin and degrades its heme group to produce the free iron it needs [49] . In this sense, AS-induced HO-1 expression may contribute to inhibit S. aureus metabolism. The AS inhibition of septic arthritis-induced cytokine production and oxidative stress lines up well with the inhibition of NF-κB activation. Downstream of ROS, it has been shown that HNO inhibits the phosphorylation of p38 mitogen-activated protein kinase and increases IκB, reducing NF-κB activation and translocation to the cell nucleus [50] . Therefore, AS exhibits consistent anti-inflammatory effects. The anti-inflammatory effects of AS were accompanied by reduced joint damaged, including histopathological cartilage and inflammation scores, proteoglycan loss, RANKL, RANK and OPG mRNA expression, and clinical severity. Thus, AS inhibited septic arthritisinduced knee joint tissue lesion, bone resorption markers and overall disease severity. Under these circumstances, AS presented a notable prominent reduction of septic arthritis inflammation and tissue damage that together would ultimately lead to loss of knee joint function.
Bacterial growth in synovial tissue correlates with the advancement of inflammation [12] . These group of data regarding analgesia, reduction of inflammation and tissue destruction lead to the question on whether such prominent effects would favor the development of local infection to systemic infection due to inadequate local control. In fact, sole inhibition of NF-κB activation facilitates S. aureus infection since this approach limits the essential inflammatory immune response against the infection [51] . However, biomarkers of systemic infection [52] such as increase in systemic cytokine levels (such TNF-α and IL-1β), leukocyte recruitment to the lungs and neutrophil entrapment (increased MPO activity) in the lungs were also substantially reduced by AS treatment compared to vehicle treated septic arthritis mice. samples were harvested and the oxidative stress was assessed by determining (A) superoxide anion production (NBT assay), (B) lipid peroxidation (TBARS assay), (C) reduced gluthathione (GSH) levels, (D) ferric reducing antioxidant power (FRAP assay) and (E) ABTS radical scavenging ability (ABTS assay). N=6 per group per experiment, representative of two independent experiments. *P < 0.05 compared with the saline group, #P < 0.05 compared with the S. aureus+vehicle group. One-way ANOVA followed by Tukey's test. Microbicidal effect was evaluated by MBC and CFU counts on agar dishes. (C) Killing assay with BMDM. N=6 per group per in vivo experiment, representative of two independent experiments *P < 0.05 compared with the saline group, #P < 0.05 compared with the S. aureus+vehicle group. One-way ANOVA followed by Tukey's test.
Therefore, it was likely that the anti-inflammatory effect was also accompanied by a better control of infection. AS treatment reduced the recovery of S. aureus CFU in knee joint and spleen samples of mice. Thus, AS controlled the infection together with the analgesic and antiinflammatory effects. In fact, AS enhanced the macrophage killing of S. aureus in a L-cystein-sensitive manner, a HNO scavenger, thus, lending further support to HNO being the accountable entity for the killing activity of AS rather than nitrite or NO • . We also observed that AS presented antimicrobial effect against S. aureus in an in vitro system without mammalian cells, demonstrating a direct bactericidal action.
S. aureus exhibit a peculiar response to redox-mediated attack. The combination between RNS, ROS or proteases, rather than single attack by NO
• or superoxide/H 2 O 2 is responsible for bactericidal action against S. aureus infection [53, 54] . Nevertheless, HNO lacks reactivity with ROS even in settings of elevated ROS [44, 55] such as infection conditions. It is likely that HNO directly reacts with bacterial components since the lipophilic characteristic of RNS allows the migration through cells, broadening the potential profile of targets and reactivity. DNA, amino acids, and proteins can be oxidized and/or modified through redox reactions. HNO induces double-and single-strand DNA breaks and base oxidation [54, 55] and it could explain, at least in part, the HNO killing mechanism of S. aureus. However, the exact mechanisms behind these data need to be further investigated to clarify the interactions of HNO with bacterial cellular components. In this sense, HNO seems to prevent the driving force behind the long-lasting joint septic inflammation, the infection it self. Nevertheless, AS also inhibits aseptic inflammation and pain [23] [24] [25] , indicating its anti-inflammatory and analgesic effects independently of the bactericidal activity. In addition, AS joins in one molecule a common therapeutic combination of an anti-inflammatory with antibiotic. A 28-day treatment protocol with AS did not alter the blood levels of AST, ALT, creatinine and urea, markers of liver [32] and renal [56] damage, further supporting the therapeutic applicability of AS.
Another aspect to be considered is that the HNO bioavailability may be augmented during disease-associated thiol (SH) depletion [57] as it occurs in inflammatory conditions. The current understanding is that thiols are key scavengers of HNO in vivo due their high affinities, and GSH that contain thiol groups has been suggested to be a key scavenger of HNO due to high intracellular concentration (1-10 mM/L) [22] . In this sense, the bioavailability is greater under oxidative stress, decreased HNO scavenging due to thiol depletion and the resistance of HNO to scavenging. Furthermore, cellular thiols could compartmentalize the action of HNO such that HNO interacts more readily with membrane-bound-biomolecules where the concentrations of scavengers such as GSH are low [16] . Undoubtedly, such compartmentalization and differential reactivity with thiols contributes to the distinct pharmacology/biology of HNO versus NO
• . As such, it may be anticipated that the HNO donor efficacy would be preserved and/or enhanced in diseases states associated with oxidative stress, such as septic arthritis. Concluding, this is the first study demonstrating that the nitroxyl donor, Angeli's salt, inhibits pain and inflammation in S. aureus-induced septic arthritis by limiting the inflammatory response and showing microbicidal effects, therefore, efficiently avoiding the loss of function related to chronic septic arthritis. experiments. *P < 0.05 compared to saline group, #P < 0.05 compared with the S. aureus+vehicle group. One-way ANOVA followed by Tukey's test.
